CA-SCIENTIST.COM
26.5.2021 13:57:05 CEST | Business Wire | Press release
Scientist.com, the pharmaceutical industry’s leading R&D marketplace, announced today that VERIF.i® , the company’s new supplier pre-assessment program, has officially launched with the successful completion of an on-site assessment of Boca Biolistics’s biorepository facilities. VERIF.i was developed to help both sides of the Scientist.com marketplace. Pre-assessments help suppliers such as Boca Biolistics demonstrate their quality and capabilities, while helping pharma and biotech customers select regulated services in an accelerated manner with more confidence and less risk.
“We have always been confident in the quality of our facilities and the personnel that operate them,” stated Joseph Mauro, Chief Vision Officer at Boca Biolistics. “VERIF.i allows us to demonstrate our expertise to current and future clients of Scientist.com’s marketplace as well as to our existing clientele outside of the platform."
Boca Biolistics is a hybrid contract research organization (CRO) with an integrated life science biorepository, offering central laboratory testing as well as clinical trial services. The company procures human biospecimens from around the world for commercial product development and the advancement of precision medicine. VERIF.i enables Boca Biolistics and other suppliers of regulated research services to communicate their standards against pre-defined criteria developed for the biopharma industry and then confirm them through independent, third-party auditors that carry out an on-site inspection.
“On-site assessments are expensive, resource intensive and time consuming for customers and suppliers,” stated Matt McLoughlin, Sr. VP of Categories and Compliance at Scientist.com. “VERIF.i standardizes and simplifies the process for both sides of the market. It enables suppliers to differentiate themselves from their peers while enabling customers to gain valuable, unbiased insight into a supplier’s facilities, personnel and processes."
VERIF.i is an expansion of Scientist.com’s award-winning COMPLi® solution. For more information visit https://www.scientist.com/verifi/
About Boca Biolistics
Boca Biolistics is a hybrid CRO leveraging our vertically integrated model to build a life sciences biorepository with industry leading clinical and molecular data sets. Our commercial biobank has >800,000 specimens available for use in R&D as well as clinical trials. Our CLIA/CAP accredited reference lab offers clinical testing as well as research testing services for diagnostic and pharma. Our CRO division provides end-to-end services for both diagnostic and biopharma clinical trials.
Visit bocabio.com to learn more.
Join us on our LinkedIn page.
About Scientist.com
Scientist.com is the pharmaceutical industry’s leading AI-powered marketplace for outsourced R&D. The marketplace simplifies R&D sourcing, saves time and money, reduces risk and provides access to the latest innovative tools and technologies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, over 80 biotechnology companies and the US National Institutes of Health (NIH).
Visit scientist.com to learn more.
Join Scientist.com on social media: LinkedIn , Twitter , YouTube , Facebook and Instagram
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005020/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lattice to Showcase Industrial FPGA Innovations at FPGAWorld Conference 202625.8.2026 22:00:00 CEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced its exhibition plan for the upcoming FPGAWorld Conference 2026, taking place on Sept. 8, 2026, in Stockholm, Sweden. As part of the event, Lattice will deliver technical presentations and host a demo showcase focused on how its low power FPGA solutions are advancing Industrial IoT and sensor bridging applications. Who: Lattice Semiconductor What / When (GMT+2): Tuesday, Sept. 8, 2026 Lattice Demo Showcase Presentations (Track: 12:20 – 13:35, Room Brave 05) “Solving Your Power Puzzle: Lattice FPGAs’ Path to Uncompromised Low Power” “Practical Security Fundamentals for FPGA Engineers” Where: AFRY, Frösundaleden 2A, 169 70 Solna, Sweden The FPGAWorld Conference is an international forum for researchers, engineers, teachers, students, and hackers. It covers topics such as complex analog/digital/software FPGA SoC systems, FPGA/ASIC-based products, educational and industrial cases,
France Becomes First Official Participant at Expo 2030 Riyadh25.8.2026 19:40:00 CEST | Press release
France is the first country to officially sign its Participation Contract for Expo 2030 Riyadh, a major milestone in its preparations and growing international momentum. The signing took place on the sidelines of the visit to France by His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825634516/en/ The ceremony in Paris was attended by H.H. Prince Faisal bin Farhan Al Saud, Minister of Foreign Affairs of the Kingdom of Saudi Arabia, and Dimitri S. Kerkentzes, Secretary General of the BIE. The Participation Contract was signed by Talal Al-Marri, Chief Executive Officer of Expo 2030 Riyadh, and Jacques Maire, Chairman of the Compagnie Française des Expositions (COFREX). The agreement formally establishes France’s participation in Expo 2030 Riyadh, providing the framework for its presence throughout the six-month event. It spec
Saudi Arabia and BIE Sign See Agreement for Expo 2030 Riyadh, Advancing Framework for International Participation25.8.2026 19:17:00 CEST | Press release
The Kingdom of Saudi Arabia and the Bureau International des Expositions (BIE) have signed the See Agreement for Expo 2030 Riyadh, formally establishing the legal and administrative framework that will support Official Participants throughout their journey to the World Expo. The signing took place on the sidelines of the visit to France by His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825419959/en/ H.H. Prince Faisal bin Farhan Al Saud, Minister of Foreign Affairs of the Kingdom of Saudi Arabia, and Dimitri S. Kerkentzes, Secretary General of the BIE, at the ceremony. The ceremony was attended by H.H. Prince Faisal bin Farhan Al Saud, Minister of Foreign Affairs of the Kingdom of Saudi Arabia, Dimitri S. Kerkentzes, Secretary General of the BIE, and Talal Al-Marri, CEO of Expo 2030 Riyadh. The See Agreement sets out the
The LYCRA Company Reimagines the Trade Show Experience at Intertextile25.8.2026 18:11:00 CEST | Press release
Immersive Co-Creation District Showcases New Fiber Innovations and Value Chain Collaboration The LYCRA Company, a global leader in fiber and technology solutions for the apparel industry, is reimagining the trade show experience at Intertextile Shanghai Apparel Fabrics Autumn Edition, which opened today in China. Building on the success of last year's ALL IN concept, the company has expanded its co-creation vision into a 356-square-meter Lifestyle District featuring partners Jingzili New Material, JYT Textile, Lianxingfa Knitting, and Trend Textile. The district is part of a larger 895-square-meter pavilion showcasing a total of 19 co-exhibitors. Together, they demonstrate how innovations in fiber, fabric, and garments can be combined to create compelling solutions for both work and play. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260821281698/en/ The LYCRA Company expands its co-creation vision through an immersive Life
BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA25.8.2026 16:40:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy is the first and only immunotherapy-based regimen to deliver more than two years of median OS in first-line HER2+ GEA, regardless of PD-L1 statusRegimen poised to become standard of care in this difficult-to-treat disease. BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of adult patients with unresectable locally advanced or metastatic HER2-positive (HER2+) gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA). The approval is supported by results from the Phase 3 HERIZON-GEA-01 trial, which were published in The New England Journal of Medicine earlier this year. GEA, which includes adenocarcinomas of the stomach, gastroesophageal junction and e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom